Home - Products - Angiogenesis - VEGFR - Semaxanib

Semaxanib

CAS No. 194413-58-6

Semaxanib ( SU5416 )

Catalog No. M13045 CAS No. 194413-58-6

Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	37	In Stock
10MG	30	In Stock
25MG	48	In Stock
50MG	71	In Stock
100MG	111	In Stock
200MG	174	In Stock
500MG	341	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Semaxanib
Note

Research use only, not for human use.
Brief Description

Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
Description

Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. Phase 3.
In Vitro

——
In Vivo

——
Synonyms

SU5416
Pathway

Angiogenesis
Target

VEGFR
Recptor

VEGFR2/Flk1
Research Area

Cancer
Indication

——

Chemical Information

CAS Number

194413-58-6
Formula Weight

238.28
Molecular Formula

C15H14N2O
Purity

>98% (HPLC)
Solubility

Ethanol: 2 mg/mL (8.39 mM); DMSO: 22 mg/mL (92.32 mM)
SMILES

CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Fong TA, et al. Y Res, 1999, 59(1), 99-106.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

TIE-2/VEGFR-2 kinase...

TIE-2/VEGFR-2 kinase-IN-5 (TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor) is a potent agent with anti-angiogenic activity, commonly used in biomedical research focused on angiogenesis.
TAK-593

TAK-593 is an effective VEGFR and PDGFR family inhibitor.
Lariciresinol

Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans. Dietary lariciresinol can attenuate mammary tumor growth and reduce blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.

Sign In Join Free